Research programme: Nav1.1 sodium channel openers - Xenon Pharmaceuticals
Alternative Names: Nav1.1 sodium channel openers - Xenon PharmaceuticalsLatest Information Update: 03 Jul 2024
At a glance
- Originator Xenon Pharmaceuticals
- Class Antiepileptic drugs
- Mechanism of Action NAV1.1 voltage-gated sodium channel stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dravet syndrome
Most Recent Events
- 03 Jul 2024 Preclinical trials in Dravet syndrome in Canada (unspecified route), July 2024 (Xenon Pharmaceuticals pipeline, July 2024)
- 03 Jul 2024 Xenon Pharmaceuticals plans to advance multiple candidates into IND-enabling studies in 2024 and 2025 (Xenon Pharmaceuticals pipeline, June 2024)
- 31 Dec 2023 Xenon Pharmaceuticals has patent pending for Nav1.1 sodium channel openers in US, before December 2023